

## DAFTAR PUSTAKA

Ajeng Putika Sari, J. B. S. E. R., 2015. Pengaruh N-asetilsistein terhadap transpor mukosilia tuba Eustachius penderita otitis media supuratif kronis tanpa kolesteatoma. *ORLI*, Volume 45.

Aldini, G. et al., 2018. N-acetylcystein as an antioxidant and disulphide breaking agent: the reason why. *Free Radical Research*, Volume 52.

Alifah, 2012. *Peranan Helicobacter Pylori Terhadap Kejadian Refluks Laringofaring Pada Penderita Refluks Laringofaring*, Makassar: s.n.

Andriani, Y., 2011. *Deteksi Pepsin Pada Penderita Reflks Laringofaring (9RLF) Yang Didiagnosis Berdasarkan Reflux Symptom Index (RSI) dan Reflux Finding Score (RFS)*, Makassar: s.n.

Anwar, G. A., 2017. *Efektivitas terapi kombinasi modifikasi diet rendah asam terhadap perbaikan klinis rfluks laringofaring*. s.l.:s.n.

Ballenger, J. J., 1994. Anatomi Bedah Faring. In: S. A. B. T. RSCM-FKUI, ed. *Penyakit Telinga, Hidung, Tenggorok, Kepala dan Leher*. Jakarta: Binarupa Aksara, p. 318.

Blumin, J. H. & Johnston, N., 2014. Laryngopharyngeal Reflux. In: *Bailey's Head and Neck Surgery-OTOLARYNGOLOGY Fifth edition*. Philadelphia: Lippincott Williams & Wilkins, p. 958.

Bulut, F. et al., 2021. Low Antioxidant Enzyme Levels and Oxidative Stress in Laryngopharyngeal Reflux (LPR) Patients. *Journal of Voice*.

Carrau, R. et al., 2004. The impact of laryngopharygeal reflux on patient reported quality of life. *Laryngoscope*.

Chae, M., Jang, D. H., Kim, H. C. & Kwon, M., 2020. A Prospective Randomized Clinical Trial Of Combination Theraphy With Proton Pump Inhibitors and Mucoytics in Patients with Laryngopharyngeal Reflux. *Annals of Otology, Rhinology & Laryngology*.

Dabirmoghaddam, P. et al., 2013. The effect of N-acetyl Cysteine on laryngopharyngeal reflux. *Acta medica Iranica*.

Dorlan, 2002. *Kamus Kedokteran Dorlan*. Jakarta: EGC.

Flora, S. D., Balansky, R. & Maestra, S. L., 2020. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. *The FASEB Journal*, 34(10).

Ford, C. N., 2005. Evaluation and Management of Laryngopharyngeal Reflux. *JAMA The Journal of the American Medical Association*.

Frenz, D. & Smith, R., 2006. Surgical Anatomy of The Pharynx and Esophagus. In: *Otolaryngology Basis science and Clinical Review*. New York: Thieme.

Frye, R. E. et al., 2019. Pharmacology, Formulations, and adverse Effects. In: R. E. Frye, ed. *The Therapeutic Use of N-Acetylcystein (NAC) in Medicine*. Singapore: Springer ANture Singapore Pte. Ltd, p. 387.

Hamidian, S. M.-T., 2015. An Additive Effect of Oral N-Acetyl Cysteine On eradication of Helicobacter Pylori. *Hindawi Publishing Corporation*, Volume 2015.

Hermani, B. & Hatauruk, S. M., 2007. Disfonia. In: E. A. Soepardi, N. Iskandar, J. Bashiruddin & R. D. Restuti, eds. *Buku Ajar Ilmu Kesehatan Telinga Hidung dan Tenggorok*. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia.

Javed, M., Ali, M. H., Tanveer, M. S. & Tanveer, M. H., 2020. Omeprazole vs Lansoprazole in the Management of Gastroesophageal Reflux Disease: A systematic Literature Review. *Journal of Medical Research and Innovation*.

Joshi, A. A., Chiplunkar, B. G., Bradoo, R. A. & Shah, K. D., 2015. Posterior Commissure Hypertrophy as Diagnostic and Prognostic Indicator for Laryngopharyngeal Reflux. *International Journal of Phonosurgery & Laryngology*.

Juniati, S. H., 2013. Anatomi Esofagus. In: S. H. Juniati, ed. *Ilmu Kesehatan THT-KL: Esofagus*. Surabaya: Pusat Penerbit dan Percetakan UNAIR.

Kedarisetty, S. & Soliman, A. M., 2019. Lifestyle and Dietary Modifications. In: *Laryngopharyngeal Reflux Disease*. Switzerland: Springer Nature Switzerland.

Kim, S. Y. et al., 2018. Multicenter Evaluation on the Efficacy of N-Acetyl Cysteine in Relieving the Symptoms of Laryngopharyngeal Reflux Disease. *Journal of The Korean Society of Laryngology, Phoniatrics and Logopedics*.

Koufman, J. A., Aviv, J. E., Casiano, R. R. & Shaw, G. Y., 2002. Laryngopharyngeal reflux: Position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of

Otolaryngology-Head and Neck Surgery. *Otolaryngology-Head and Neck Surgery*, Volume 127.

Kowalik, K. & Krzeski, A., 2017. The Role of Pepsin in The Laryngopharyngeal Reflux. *Otolaryngologia Polska*.

Kuo, C. L., 2019. Laryngopharyngeal Reflux: An Update. *Archives of Otorhinolaryngology-Head & Neck Surgery*.

Kurniawati, T., Madiadipoera, T., Sarbini, T. B. & Saifuddin, O. M., 2012. Perbandingan Efektivitas antara Omeprazol dan Lansoprazol terhadap Perbaikan Kualitas Hidup Penderita Rinosinusitis Kronik Akibat Refluks Laringofaring. *Bandung Medical Journal*, Volume 44.

Latupono, A., 2021. *Perbandingan Nilai Mean Nocturnal Baseline Impedance (MNBI) Distal dan Proksimal Pada Penderita Refluks Laringofaring (RLF) Berdasarkan Karakteristik Refluks*. Makassar: s.n.

Lechien, J. R. et al., 2019. Evaluation and Management of Laryngopharyngeal Reflux Disease: State of the Art Review. *Otolaryngol Head Neck Surg*.

Lechien, J. R. et al., 2021. Laryngopharyngeal reflux disease is more severe in obese patients: A prospective multicenter study. *The Laryngoscope*.

Lechien, J. R. et al., 2021. Influence of Age and Sex on Clinical and Therapeutic Features of Laryngopharyngeal Reflux. *American Academy of Otolaryngology-Head and Neck Surgery*.

Liu, D., Qian, T., Sun, S. & Jiang, J. J., 2020. Laryngopharyngeal Reflux and Inflammatory Responses in Mucosal Barrier Dysfunction of the Upper Aerodigestive Tract. *Journal of Inflammation Research* .

Martinucci, I. et al., 2013. Optimal treatment of laryngopharyngeal reflux disease. *Therapeutic Advances in Chronic Disease*.

Mokhtari, V. et al., 2017. A review on various uses of N-acetyl cystein. *Cell Journal*, Volume 19, pp. 11-17.

Morrison, M. P. & Anderson, D. C., 2019. Laryngopharyngeal Reflux. In: N. Jamal & M. B. Wang, eds. *Laryngopharyngeal Reflux Disease*. Switzerland: Springer, p. 3.

Netter, F. H., 2014. Head And Neck. In: *Atlas Of Human Anatomy*. Philadelphia: Saunders-Elsevier, p. 64.

Calverley, P., Rogliani, P. & Papi, A., 2020. Safety of N-Acetylcystein at High Doses in Chronic Respiratory Disease: A Review. *Drug Safety*.

Park KH, C. S., 2006. Diagnosis Of Laryngopharyngeal Reflux Among Globus Patients. *Otolarygol Head Neck Surg*.

Pramana, C., Muyyasaroh & Antono, D., 2014. Pengaruh Suplementasi Zinc Terhadap Perbaikan Klinis Penderita Laryngopharyngeal Reflux Disease. *ORLI*, Volume 44.

Ratunanda, S. S. et al., 2018. Refluks Helicobacter pylori di mukosa hidung penderita rinosinusitis kronik disertai refluks laringofaring. *ORLI*, Volume 48.

Rees, C. J. & Belafsky, P. C., 2008. Laryngopharyngeal reflux: Current concepts in pathophysiology, diagnosis, and treatment. *International Journal of Speech-Language Pathology*.

Salihfendic, N., Zildzic, M. & Cabric, . E., 2017. Laryngopharyngeal Reflux Disease – LPRD. *PROFESSIONAL PAPER*.

Santeerapharp, A., Wiryaamornchai, P. & Hunchaisri, N., 2017. Comparison between Omeprazole Plus Baclofen and Omeprazole Plus Placebo in the Treatment of Laryngopharyngeal Reflux. *Journal of Medical Association of Thailand*, Volume 100.

Shi, Z. & Puto, C. A., 2020. N-Acetylcysteine to Combat COVID-19: An Evidence Review. *Dovepress*.

Silbernagl, 2000. *Color Atlas of Pathophysiology*. New York: Thieme.

Standring, S., ed., 2016. Larynx. In: *Anatomy-The Anatomical Basis of Clinical Practice*. United State: Elsevier.

Standring, S., ed., 2016. Pharynx. In: *Anatomy-The Anatomical Basis of Clinical Practice*. US: Elsevier, p. 577.

Tardiolo, G., Bramanti, P. & Mazzon, E., 2018. Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. *Molecules*.

Tortora, G. J. & Derrickson, B., 2009. The Digestive System. In: *Principles Of Anatomy and Physiology*. United States of America: John Wiley&Sons, Inc, p. 935.

Wood, J. M. et al., 2011. Biomarkers and laryngopharyngeal reflux. *The Journal of Laryngology & Otology* .

## LAMPIRAN 1

Seluruh data yang diperoleh berdasarkan hasil anamnesis, pemeriksaan fisik dan endoskopi laring yang kemudian dituliskan pada formulir di bawah ini

Nama :  
Umur :  
Jenis Kelamin :  
BB :  
TB :  
IMT :  
Anamnesa :

-----  
-----  
-----  
-----  
-----  
-----  
-----

Riwayat alergi obat : -----

Pemeriksaan Fisik :

-----  
-----  
-----  
-----  
-----

**REFLUX SYMPTOM INDEX (RSI)**

| No.   | Dalam satu bulan terakhir, apakah anda menderita atau ada keluhan      | 0 = tidak ada keluhan<br>5 = sangat berat |   |   |   |   |   |
|-------|--|---|---|---|---|---|---|
|       |  | 0   | 1 | 2 | 3 | 4 | 5 |
| 1.    | Suara serak/problem suara  |   |   |   |   |   |   |
| 2.    | Mendehem ( <i>throat clearing</i> )                                    |   |   |   |   |   |   |
| 3.    | Lendir di tenggorokan  |   |   |   |   |   |   |
| 4.    | Sulit menelan makanan padat, cair atau pil                             |   |   |   |   |   |   |
| 5.    | Batuk setelah makan atau berbaring                                     |   |   |   |   |   |   |
| 6.    | Kesukaran bernafas atau rasa tercekik                                  |   |   |   |   |   |   |
| 7.    | Batuk yang mengganggu  |   |   |   |   |   |   |
| 8.    | Rasa mengganjal di tenggorokan   |   |   |   |   |   |   |
| 9.    | Dada rasa panas, nyeri dada, gangguan pencernaan atau regurgitasi asam |   |   |   |   |   |   |
| Total |  |   |   |   |   |   |   |

**REFLUX FINDING SCORE (RFS)**

| No      | Temuan                           | Nilai   |
|---------|----------------------------------|---|
| 1.      | Edema subglotik                  | 0 : Tidak ada<br>2 : Ada  |
| 2.      | Obliterasi ventrikular           | 0 : Tidak ada<br>2 : Parsial<br>4 : Komplit                               |
| 3.      | Eritema/hyperemia                | 0 : Tidak ada<br>2 : Hanya aritenoid<br>4 : Difus                         |
| 4.      | Edema pita suara                 | 0 : Tidak ada<br>1 : Ringan<br>2 : Moderat<br>3 : Berat<br>4 : Polipoid   |
| 5.      | Edema laring difus               | 0 : Tidak ada<br>1 : Ringan<br>2 : Moderat<br>3 : Berat<br>4 : Obstruktif |
| 6.      | Hipertrofi komisura posterior    | 0 : Tidak ada<br>1 : Ringan<br>2 : Moderat<br>3 : Berat<br>4 : Obstruktif |
| 7.      | Granuloma/jaringan granulasi     | 0 : Tidak ada<br>2 : Ada  |
| 8.      | <i>Thick endolaryngeal mucus</i> | 0 : Tidak ada<br>2 : Ada  |
| Total : |                                  |   |



## LAMPIRAN 2

### Surat Rekomendasi Persetujuan Etik



#### REKOMENDASI PERSETUJUAN ETIK

Nomor : 766/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 3 Desember 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

|                                    |   |                     |                           |
|------------------------------------|---|---------------------|---------------------------|
| No Protokol                        | UH21100612  | No Sponsor Protokol |                           |
| Peneliti Utama                     | <b>dr. Yanneca Bamba Pirade</b>   | Sponsor             |                           |
| Judul Peneliti                     | Pengaruh Pemberian N-Asetilsistein Terhadap Perbaikan Klinis Penderita Refluks Laringofaring Berdasarkan Reflux Symptom Index Dan Reflux Finding Score  |                     |                           |
| No Versi Protokol                  | <b>2</b>  | Tanggal Versi       | <b>1 Nopember 2021</b>    |
| No Versi PSP                       | <b>2</b>  | Tanggal Versi       | <b>1 Nopember 2021</b>    |
| Tempat Penelitian                  | RS Dr. Wahidin Sudirohusodo dan RS Pelamonia Makassar   |                     |                           |
| Jenis Review                       | <input type="checkbox"/> Exempted<br><input type="checkbox"/> Expedited<br><input checked="" type="checkbox"/> Fullboard Tanggal <b>21 Oktober 2021</b> | Masa Berlaku        | Frekuensi review lanjutan |
| Ketua KEPK FKUH RSUH dan RSWS      | Nama<br><b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>   | Tanda tangan        |                           |
| Sekretaris KEPK FKUH RSUH dan RSWS | Nama<br><b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>  | Tanda tangan        |                           |

#### Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

**LAMPIRAN 3**  
**DOKUMENTASI KEGIATAN**



## LAMPIRAN 4. Data Dasar Penelitian

### RSI Kelompok Perlakuan (PPI+NAC)

| NO | IDENTITAS | JK | Usia | BB | TB  | IMT   | Lama sakit | RSI (sebelum terapi) |    |    |    |     |    |    |    |     | RSI (sesudah terapi 1 bulan) |    |    |    |    |     |    |    |    |     |       |
|----|-----------|----|------|----|-----|-------|------------|----------------------|----|----|----|-----|----|----|----|-----|------------------------------|----|----|----|----|-----|----|----|----|-----|-------|
|    |           |    |      |    |     |       |            | SS                   | Md | LT | SM | Btk | SB | BM | RM | H,R | TOTAL                        | SS | Md | LT | SM | Btk | SB | BM | RM | H,R | TOTAL |
| 1  | R         | P  | 49   | 54 | 160 | 21.09 | 3 bulan    | 0                    | 1  | 4  | 2  | 2   | 0  | 1  | 3  | 4   | 13                           | 0  | 0  | 2  | 1  | 0   | 0  | 0  | 2  | 0   | 5     |
| 2  | M         | P  | 55   | 40 | 150 | 17.78 | 8 bulan    | 0                    | 4  | 1  | 3  | 0   | 0  | 0  | 5  | 1   | 14                           | 0  | 1  | 0  | 0  | 0   | 1  | 0  | 4  | 0   | 6     |
| 3  | K         | L  | 36   | 76 | 176 | 24.53 | 3 bulan    | 0                    | 0  | 2  | 1  | 4   | 1  | 2  | 4  | 0   | 14                           | 0  | 3  | 3  | 0  | 1   | 0  | 3  | 4  | 3   | 17    |
| 4  | S         | P  | 32   | 53 | 153 | 22.64 | 5 bulan    | 0                    | 2  | 4  | 0  | 0   | 0  | 0  | 4  | 4   | 14                           | 0  | 2  | 3  | 0  | 0   | 0  | 0  | 4  | 4   | 13    |
| 5  | N         | P  | 46   | 69 | 172 | 23.32 | 4 bulan    | 0                    | 4  | 2  | 0  | 0   | 2  | 3  | 4  | 2   | 17                           | 0  | 3  | 2  | 0  | 0   | 3  | 2  | 2  | 3   | 15    |
| 6  | E         | P  | 28   | 64 | 157 | 21.63 | 1 bulan    | 3                    | 2  | 3  | 4  | 2   | 3  | 2  | 4  | 3   | 26                           | 3  | 3  | 3  | 3  | 1   | 2  | 1  | 4  | 3   | 23    |
| 7  | B         | P  | 41   | 42 | 150 | 18.67 | 1 tahun    | 0                    | 2  | 5  | 0  | 0   | 0  | 0  | 5  | 2   | 14                           | 2  | 2  | 3  | 2  | 1   | 0  | 0  | 4  | 2   | 16    |
| 8  | J         | P  | 38   | 59 | 152 | 25.54 | 1 bulan    | 1                    | 3  | 4  | 0  | 0   | 0  | 0  | 3  | 2   | 13                           | 2  | 0  | 4  | 0  | 0   | 0  | 0  | 3  | 2   | 11    |
| 9  | AA        | L  | 36   | 65 | 165 | 23.87 | 1 tahun    | 0                    | 1  | 3  | 1  | 0   | 0  | 0  | 5  | 3   | 13                           | 0  | 1  | 1  | 0  | 0   | 0  | 1  | 2  | 1   | 6     |
| 10 | SH        | P  | 56   | 54 | 152 | 23.37 | 1 bulan    | 2                    | 1  | 2  | 2  | 2   | 1  | 0  | 2  | 3   | 15                           | 1  | 1  | 1  | 1  | 0   | 0  | 0  | 2  | 3   | 9     |
| 11 | E         | P  | 58   | 50 | 152 | 21.64 | 1 bulan    | 3                    | 5  | 3  | 5  | 0   | 0  | 0  | 4  | 3   | 23                           | 0  | 1  | 2  | 0  | 0   | 0  | 1  | 2  | 1   | 7     |
| 12 | N         | P  | 45   | 45 | 146 | 21.11 | 3 bulan    | 1                    | 2  | 2  | 0  | 0   | 0  | 0  | 5  | 3   | 13                           | 0  | 1  | 1  | 0  | 0   | 0  | 0  | 4  | 2   | 8     |
| 13 | A         | L  | 44   | 66 | 161 | 25.46 | 2 bulan    | 3                    | 3  | 3  | 3  | 0   | 0  | 0  | 3  | 2   | 17                           | 2  | 2  | 3  | 0  | 1   | 0  | 0  | 2  | 2   | 12    |
| 14 | AM        | L  | 51   | 55 | 163 | 20.70 | 2 tahun    | 2                    | 3  | 5  | 0  | 0   | 0  | 0  | 5  | 2   | 17                           | 0  | 1  | 2  | 0  | 0   | 0  | 0  | 2  | 0   | 5     |
| 15 | IL        | L  | 32   | 54 | 161 | 20.83 | 1 bulan    | 4                    | 3  | 4  | 0  | 0   | 0  | 4  | 4  | 0   | 19                           | 0  | 1  | 1  | 0  | 0   | 0  | 0  | 3  | 0   | 5     |
| 16 | R         | L  | 54   | 81 | 160 | 31.64 | 1 tahun    | 0                    | 2  | 4  | 4  | 0   | 0  | 0  | 4  | 0   | 14                           | 0  | 0  | 3  | 4  | 0   | 0  | 0  | 1  | 0   | 8     |
| 17 | Ra        | P  | 56   | 50 | 152 | 21.64 | 4 bulan    | 0                    | 3  | 2  | 0  | 0   | 0  | 0  | 4  | 4   | 13                           | 0  | 5  | 2  | 0  | 0   | 1  | 0  | 5  | 3   | 16    |
| 18 | N         | P  | 44   | 54 | 152 | 23.37 | 6 bulan    | 1                    | 3  | 3  | 0  | 0   | 0  | 0  | 4  | 2   | 13                           | 0  | 2  | 2  | 0  | 1   | 0  | 0  | 3  | 2   | 10    |

#### Keterangan

|      |                               |
|------|-------------------------------|
| SS   | Suara serak                   |
| Md   | Mendehem                      |
| Lt   | Lendir di tenggorok           |
| SM   | Sukar menelan                 |
| Btk  | Batuk setelah makan/berbaring |
| SB   | Sukar bernafas                |
| BM   | Batuk mengganggu              |
| RM   | Rasa mengganjal di tenggorok  |
| H, R | Dada rasa panas, regurgitasi  |

## RFS Kelompok perlakuan

| No | Identitas | RFS (sebelum terapi) |    |     |     |     |     |   |     |       | RFS (sesudah terapi 1 bulan) |    |     |     |     |     |   |     |       |
|----|-----------|----------------------|----|-----|-----|-----|-----|---|-----|-------|------------------------------|----|-----|-----|-----|-----|---|-----|-------|
|    |           | Esg                  | OV | E/H | EPS | ELD | HKP | G | PSE | TOTAL | Esg                          | OV | E/H | EPS | ELD | HKP | G | PSE | TOTAL |
| 1  | R         | 0                    | 4  | 4   | 0   | 2   | 3   | 0 | 2   | 15    | 0                            | 4  | 2   | 0   | 0   | 0   | 0 | 0   | 6     |
| 2  | M         | 2                    | 0  | 2   | 1   | 1   | 0   | 0 | 2   | 8     | 2                            | 4  | 2   | 0   | 0   | 1   | 0 | 0   | 9     |
| 3  | K         | 0                    | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 7     | 0                            | 0  | 2   | 0   | 0   | 0   | 2 | 2   | 6     |
| 4  | S         | 0                    | 4  | 2   | 0   | 0   | 1   | 0 | 2   | 8     | 0                            | 0  | 2   | 0   | 0   | 0   | 0 | 0   | 2     |
| 5  | N         | 0                    | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 8     | 0                            | 2  | 0   | 0   | 0   | 1   | 0 | 0   | 3     |
| 6  | E         | 0                    | 2  | 2   | 0   | 1   | 2   | 2 | 0   | 9     | 0                            | 2  | 2   | 0   | 2   | 2   | 2 | 0   | 10    |
| 7  | B         | 0                    | 4  | 2   | 2   | 2   | 2   | 2 | 2   | 16    | 0                            | 0  | 2   | 1   | 0   | 1   | 0 | 2   | 6     |
| 8  | J         | 0                    | 0  | 2   | 0   | 1   | 2   | 0 | 2   | 7     | 2                            | 0  | 0   | 0   | 0   | 1   | 0 | 0   | 3     |
| 9  | AA        | 2                    | 2  | 2   | 1   | 0   | 1   | 0 | 0   | 8     | 0                            | 4  | 2   | 0   | 2   | 2   | 2 | 2   | 14    |
| 10 | SH        | 0                    | 0  | 2   | 1   | 0   | 2   | 0 | 2   | 7     | 2                            | 0  | 2   | 0   | 0   | 1   | 0 | 2   | 7     |
| 11 | E         | 2                    | 2  | 2   | 1   | 0   | 2   | 0 | 2   | 11    | 0                            | 0  | 0   | 0   | 0   | 1   | 0 | 0   | 1     |
| 12 | N         | 2                    | 0  | 4   | 1   | 0   | 1   | 0 | 0   | 7     | 2                            | 2  | 2   | 1   | 0   | 0   | 0 | 0   | 6     |
| 13 | A         | 2                    | 4  | 4   | 1   | 0   | 1   | 0 | 2   | 13    | 2                            | 2  | 2   | 1   | 0   | 1   | 0 | 2   | 11    |
| 14 | AM        | 2                    | 2  | 2   | 1   | 0   | 1   | 0 | 0   | 8     | 0                            | 2  | 0   | 0   | 1   | 1   | 0 | 0   | 4     |
| 15 | IL        | 0                    | 0  | 2   | 0   | 0   | 1   | 2 | 2   | 7     | 0                            | 0  | 0   | 0   | 0   | 0   | 2 | 2   | 4     |
| 16 | R         | 2                    | 4  | 4   | 0   | 1   | 1   | 0 | 0   | 12    | 2                            | 2  | 2   | 0   | 0   | 1   | 0 | 0   | 7     |
| 17 | Ra        | 2                    | 2  | 2   | 0   | 1   | 1   | 2 | 2   | 12    | 2                            | 2  | 2   | 0   | 0   | 1   | 0 | 0   | 7     |
| 18 | N         | 2                    | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 9     | 2                            | 2  | 0   | 0   | 0   | 1   | 0 | 0   | 5     |

### Keterangan

|     |                               |
|-----|-------------------------------|
| Esg | Edema Subglotik               |
| OV  | Obliterasi ventrikuler        |
| E/H | Eritema/Hiperemis             |
| EPS | Edema pita suara              |
| ELD | edema laring difus            |
| HKP | Hipertrofi komisura posterior |
| G   | Granuloma/jaringan granulasi  |
| PSE | Penebalan sekret endolaring   |

## RSI Kelompok kontrol (PPI)

| NO | IDENTITAS | JK | Usia | BB | TB  | IMT   | Lama sakit | RSI (sebelum terapi) |    |    |    |     |    |    |    |     |       | RSI (sesudah terapi 1 bulan) |    |    |    |     |    |    |    |     |       |
|----|-----------|----|------|----|-----|-------|------------|----------------------|----|----|----|-----|----|----|----|-----|-------|------------------------------|----|----|----|-----|----|----|----|-----|-------|
|    |           |    |      |    |     |       |            | SS                   | Md | LT | SM | Btk | SB | BM | RM | H,R | TOTAL | SS                           | Md | LT | SM | Btk | SB | BM | RM | H,R | TOTAL |
| 1  | HS        | P  | 48   | 64 | 160 | 25    | 3 bulan    | 0                    | 3  | 4  | 0  | 0   | 0  | 0  | 5  | 1   | 13    | 0                            | 2  | 2  | 0  | 0   | 0  | 0  | 2  | 3   | 9     |
| 2  | R         | P  | 30   | 57 | 159 | 22.55 | 1 tahun    | 4                    | 2  | 3  | 0  | 0   | 0  | 0  | 3  | 1   | 14    | 1                            | 2  | 4  | 4  | 0   | 1  | 2  | 5  | 4   | 23    |
| 3  | A         | P  | 53   | 68 | 154 | 28.67 | 1 tahun    | 2                    | 1  | 4  | 2  | 1   | 0  | 1  | 4  | 4   | 19    | 1                            | 1  | 1  | 0  | 0   | 0  | 0  | 1  | 2   | 6     |
| 4  | NU        | P  | 40   | 63 | 156 | 25.89 | 1 tahun    | 0                    | 3  | 4  | 0  | 1   | 0  | 0  | 4  | 1   | 13    | 0                            | 2  | 3  | 0  | 1   | 0  | 1  | 3  | 1   | 11    |
| 5  | SM        | P  | 25   | 41 | 148 | 18.72 | 3 bulan    | 0                    | 2  | 5  | 1  | 0   | 3  | 3  | 3  | 3   | 20    | 0                            | 1  | 4  | 0  | 0   | 2  | 1  | 0  | 3   | 11    |
| 6  | M         | P  | 50   | 50 | 153 | 21.36 | 2 bulan    | 3                    | 0  | 5  | 3  | 4   | 0  | 0  | 3  | 0   | 18    | 3                            | 0  | 2  | 2  | 2   | 0  | 0  | 3  | 0   | 12    |
| 7  | A         | P  | 21   | 45 | 150 | 20    | 1 tahun    | 4                    | 3  | 3  | 4  | 3   | 4  | 4  | 4  | 3   | 29    | 3                            | 3  | 2  | 0  | 2   | 2  | 3  | 3  | 0   | 18    |
| 8  | HU        | P  | 47   | 54 | 158 | 21.63 | 2 bulan    | 0                    | 5  | 1  | 0  | 0   | 0  | 0  | 5  | 2   | 13    | 0                            | 1  | 0  | 1  | 0   | 0  | 0  | 3  | 0   | 5     |
| 9  | NU        | P  | 44   | 63 | 153 | 26.91 | 10 bulan   | 1                    | 2  | 3  | 1  | 3   | 0  | 0  | 4  | 3   | 17    | 0                            | 1  | 3  | 0  | 1   | 1  | 0  | 2  | 1   | 9     |
| 10 | RS        | P  | 36   | 45 | 158 | 18.02 | 8 bulan    | 0                    | 2  | 3  | 1  | 1   | 1  | 2  | 3  | 3   | 14    | 0                            | 1  | 3  | 0  | 1   | 0  | 1  | 3  | 1   | 10    |
| 11 | HA        | P  | 49   | 57 | 144 | 27.49 | 3 bulan    | 2                    | 0  | 4  | 0  | 1   | 0  | 3  | 1  | 3   | 14    | 1                            | 2  | 3  | 0  | 1   | 2  | 1  | 3  | 1   | 14    |
| 12 | SH        | P  | 60   | 49 | 145 | 23.30 | 2 tahun    | 0                    | 0  | 4  | 0  | 4   | 0  | 3  | 4  | 4   | 19    | 0                            | 0  | 3  | 0  | 2   | 0  | 3  | 4  | 2   | 14    |
| 13 | MI        | P  | 51   | 66 | 150 | 29.33 | 1 tahun    | 1                    | 0  | 3  | 5  | 1   | 1  | 0  | 3  | 4   | 18    | 1                            | 0  | 2  | 3  | 1   | 0  | 0  | 3  | 3   | 13    |
| 14 | VA        | P  | 36   | 70 | 160 | 27.34 | 2 tahun    | 1                    | 3  | 2  | 0  | 1   | 0  | 1  | 4  | 3   | 15    | 1                            | 3  | 2  | 0  | 0   | 0  | 0  | 4  | 2   | 12    |
| 15 | H         | P  | 23   | 50 | 159 | 19.78 | 1 tahun    | 4                    | 2  | 4  | 0  | 0   | 0  | 0  | 3  | 1   | 14    | 3                            | 2  | 4  | 0  | 0   | 0  | 0  | 2  | 1   | 12    |
| 16 | NU        | P  | 47   | 44 | 158 | 17.62 | 2 tahun    | 0                    | 3  | 3  | 3  | 2   | 0  | 0  | 4  | 5   | 20    | 0                            | 3  | 3  | 1  | 2   | 0  | 0  | 3  | 3   | 15    |
| 17 | NI        | P  | 35   | 58 | 156 | 23.83 | 3 tahun    | 2                    | 2  | 3  | 2  | 1   | 2  | 1  | 1  | 3   | 17    | 1                            | 0  | 2  | 0  | 2   | 1  | 0  | 3  | 3   | 12    |
| 18 | AR        | L  | 60   | 52 | 161 | 20.06 | 7 bulan    | 5                    | 1  | 5  | 2  | 0   | 0  | 0  | 2  | 0   | 15    | 3                            | 1  | 3  | 1  | 0   | 0  | 0  | 2  | 0   | 10    |

### Keterangan

|     |                               |
|-----|-------------------------------|
| SS  | Suara serak                   |
| Md  | Mendehem                      |
| Lt  | Lendir di tenggorok           |
| SM  | Sukar menelan                 |
| Btk | Batuk setelah makan/berbaring |
| SB  | Sukar bernafas                |

BM Batuk mengganggu  
 RM Rasa mengganjal di tenggorok  
 H, R Dada rasa panas, regurgitasi

### RFS Kelompok kontrol

| No | Identitas | RFS (sebelum terapi) |    |     |     |     |     |   |     |       | RFS (sesudah terapi 1 bulan) |    |     |     |     |     |   |     |       |
|----|-----------|----------------------|----|-----|-----|-----|-----|---|-----|-------|------------------------------|----|-----|-----|-----|-----|---|-----|-------|
|    |           | Esg                  | OV | E/H | EPS | ELD | HKP | G | PSE | TOTAL | Esg                          | OV | E/H | EPS | ELD | HKP | G | PSE | TOTAL |
| 1  | HS        | 2                    | 2  | 2   | 1   | 0   | 1   | 0 | 0   | 8     | 0                            | 4  | 2   | 0   | 0   | 1   | 0 | 0   | 7     |
| 2  | R         | 0                    | 0  | 2   | 0   | 0   | 2   | 0 | 2   | 7     | 2                            | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 9     |
| 3  | A         | 0                    | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 8     | 0                            | 2  | 0   | 0   | 0   | 1   | 0 | 2   | 5     |
| 4  | NU        | 0                    | 0  | 2   | 0   | 0   | 3   | 0 | 2   | 7     | 0                            | 0  | 2   | 0   | 0   | 2   | 0 | 0   | 4     |
| 5  | SM        | 2                    | 2  | 2   | 1   | 0   | 2   | 0 | 2   | 11    | 2                            | 0  | 0   | 0   | 0   | 1   | 0 | 0   | 3     |
| 6  | M         | 2                    | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 10    | 0                            | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 8     |
| 7  | A         | 0                    | 2  | 2   | 0   | 0   | 3   | 0 | 2   | 9     | 0                            | 0  | 2   | 0   | 0   | 2   | 0 | 2   | 6     |
| 8  | HU        | 2                    | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 10    | 2                            | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 9     |
| 9  | NU        | 2                    | 0  | 2   | 1   | 0   | 2   | 0 | 2   | 9     | 0                            | 0  | 2   | 0   | 0   | 0   | 0 | 2   | 4     |
| 10 | RS        | 0                    | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 7     | 0                            | 0  | 2   | 0   | 0   | 1   | 0 | 2   | 5     |
| 11 | HA        | 0                    | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 8     | 0                            | 0  | 2   | 0   | 0   | 1   | 0 | 2   | 5     |
| 12 | SH        | 2                    | 0  | 2   | 0   | 0   | 1   | 0 | 2   | 7     | 2                            | 0  | 2   | 0   | 0   | 1   | 0 | 2   | 7     |
| 13 | MI        | 0                    | 2  | 2   | 0   | 0   | 2   | 2 | 0   | 8     | 0                            | 0  | 2   | 0   | 0   | 1   | 0 | 2   | 5     |
| 14 | VA        | 0                    | 2  | 2   | 2   | 0   | 1   | 2 | 2   | 11    | 0                            | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 11    |
| 15 | H         | 0                    | 2  | 2   | 0   | 0   | 1   | 0 | 2   | 7     | 0                            | 2  | 2   | 0   | 0   | 0   | 0 | 2   | 6     |
| 16 | NU        | 2                    | 2  | 2   | 0   | 0   | 2   | 0 | 2   | 10    | 0                            | 2  | 2   | 0   | 0   | 0   | 0 | 0   | 4     |
| 17 | NI        | 0                    | 2  | 4   | 0   | 2   | 1   | 2 | 2   | 13    | 0                            | 2  | 2   | 0   | 1   | 1   | 2 | 2   | 10    |
| 18 | AR        | 2                    | 2  | 4   | 2   | 2   | 2   | 0 | 2   | 16    | 2                            | 2  | 2   | 1   | 0   | 2   | 0 | 2   | 11    |

Esg Edema Subglotik  
 OV Obliterasi ventrikuler  
 E/H Eritema/Hiperemis  
 EPS Edema pita suara  
 ELD edema laring difus  
 HKP Hipertrofi komisura posterior  
 PSE Granuloma/jaringan granulasi  
 Penebalan sekret endolaring

